Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 trial of ELI-002 in patients with KRAS-mutated pancreatic adenocarcinoma

Next Previous
Trial Profile

Phase 3 trial of ELI-002 in patients with KRAS-mutated pancreatic adenocarcinoma

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 07 Apr 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ELI 002 (Primary)
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Registrational; Therapeutic Use

Most Recent Events

  • 12 Mar 2026 According to an Elicio Therapeutics media release, the company will finalize the Phase 3 protocol and advance ELI-002 7P toward initiation of a registrational study following the primary DFS endpoint analysis in Phase 2 AMPLIFY-7P trial, subject to regulatory alignment.
  • 05 Aug 2025 According to an Elicio Therapeutics media release, company plans to request an End-of-Phase 2 meeting with the FDA to finalize the regulatory strategy for the ELI-002 planned pivotal Phase 3 study.
  • 31 Mar 2025 According to Elicio Therapeutics media release, the company is Potential to finalize this pivotal Phase 3 trial protocol for ELI-002 in resected mKRAS PDAC in H2 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top